These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 28412066)

  • 21. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan.
    Wu WC; Yeh PT; Chen SN; Yang CM; Lai CC; Kuo HK
    Ophthalmology; 2011 Jan; 118(1):176-83. PubMed ID: 20673589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children.
    Kabataş EU; Kurtul BE; Altıaylık Özer P; Kabataş N
    Curr Eye Res; 2017 Jul; 42(7):1054-1058. PubMed ID: 28128986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of clinical outcomes of conbercept versus ranibizumab treatment for retinopathy of prematurity: a multicentral prospective randomised controlled trial.
    Wu Z; Zhao J; Lam W; Yang M; Chen L; Huang X; Wei M; Yang H; Lv F; Zhang F; Zeng J; Zhang GM
    Br J Ophthalmol; 2022 Jul; 106(7):975-979. PubMed ID: 33637618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan.
    Wu WC; Kuo HK; Yeh PT; Yang CM; Lai CC; Chen SN
    Am J Ophthalmol; 2013 Jan; 155(1):150-158.e1. PubMed ID: 22967867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spectral-Domain OCT Analyses of Macular Changes After Ranibizumab Therapy for Type 1 Retinopathy of Prematurity.
    Erol MK; Coban DT; Özdemir Ö; Tunay ZÖ; Bilgin AB; Dogan B
    J Pediatr Ophthalmol Strabismus; 2015; 52(3):152-8. PubMed ID: 25859685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aqueous cytokine levels associated with severity of type 1 retinopathy of prematurity and treatment response to ranibizumab.
    Lyu J; Zhang Q; Jin H; Xu Y; Chen C; Ji X; Zhang X; Rao Y; Zhao P
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1469-1477. PubMed ID: 29948178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity.
    Sukgen EA; Koçluk Y
    Graefes Arch Clin Exp Ophthalmol; 2019 Jan; 257(1):49-55. PubMed ID: 30397793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Favorable outcomes in the treatment of aggressive posterior retinopathy of prematurity.
    Sahinoglu-Keskek N; Akkoyun I; Torer B
    Eur J Ophthalmol; 2021 Jan; 31(1):179-183. PubMed ID: 31718282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy.
    Chan JJT; Lam CPS; Kwok MKM; Wong RLM; Lee GKY; Lau WWY; Yam JCS
    Sci Rep; 2016 Jun; 6():27082. PubMed ID: 27256987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment for stage 4A retinopathy of prematurity: laser and/or ranibizumab.
    Sukgen EA; Koçluk Y
    Graefes Arch Clin Exp Ophthalmol; 2017 Feb; 255(2):263-269. PubMed ID: 27495302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity.
    Cheng Y; Zhu X; Linghu D; Liang J
    Acta Ophthalmol; 2020 Dec; 98(8):e1004-e1008. PubMed ID: 32385940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
    Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
    Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repeated intravitreal ranibizumab for reactivated retinopathy of prematurity after intravitreal ranibizumab monotherapy: vascular development analysis.
    Xia F; Lyu J; Peng J; Zhao P
    Graefes Arch Clin Exp Ophthalmol; 2022 Sep; 260(9):2837-2846. PubMed ID: 35438363
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravitreal Bevacizumab for Zone II Retinopathy of Prematurity.
    Larrañaga-Fragoso P; Peralta J; Bravo-Ljubetic L; Pastora N; Abelairas-Gómez J
    J Pediatr Ophthalmol Strabismus; 2016 Nov; 53(6):375-382. PubMed ID: 27537247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FLUORESCEIN ANGIOGRAPHIC EVALUATION OF PERIPHERAL RETINAL VASCULATURE AFTER PRIMARY INTRAVITREAL RANIBIZUMAB FOR RETINOPATHY OF PREMATURITY.
    Harper CA; Wright LM; Young RC; Read SP; Chang EY
    Retina; 2019 Apr; 39(4):700-705. PubMed ID: 29300248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER BEVACIZUMAB OR RANIBIZUMAB TREATMENT FOR RETINOPATHY OF PREMATURITY.
    Wu WC; Shih CP; Lien R; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
    Retina; 2017 Apr; 37(4):694-701. PubMed ID: 27467377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity.
    Erol MK; Coban DT; Sari ES; Bilgin AB; Dogan B; Ozdemir O; Tunay ZO
    Arq Bras Oftalmol; 2015; 78(6):340-3. PubMed ID: 26677033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab.
    Chen SN; Lian I; Hwang YC; Chen YH; Chang YC; Lee KH; Chuang CC; Wu WC
    Retina; 2015 Apr; 35(4):667-74. PubMed ID: 25462435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity.
    Salman AG; Said AM
    Ophthalmic Res; 2015; 53(1):15-20. PubMed ID: 25471087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravitreal Ranibizumab Injection for the Treatment of Retinopathy of Prematurity.
    Aldebasi T; Guma MA; Bashir R; Al Saif S; Altwaijri WA; Al Bekairy AM
    Med Princ Pract; 2019; 28(6):526-532. PubMed ID: 30995663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.